Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05941793 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
A Phase 2 study of Mild to Moderate COVID-19, sponsored by Oneness Biotech Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 5
- Study locations
NCT05941793 is a Phase 2 study of Mild to Moderate COVID-19 that has completed, run by Oneness Biotech Co.. The registered enrollment target is 135 participants. The trial reports 5 study locations across 2 states.
The verdict
NCT05941793, a Phase 2 study of Mild to Moderate COVID-19, has completed, sponsored by Oneness Biotech Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants with Mild to Moderate COVID-19
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MBS-COV
Study Locations (5)
Other
- Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare - New Taipei City
- National Taiwan University Hospital - Taipei
- Taipei Medical University Hospital - Taipei
- Taipei Municipal Wanfang Hospital - Taipei
Utah
- Velocity Clinical Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2024-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05941793
The ClinicalTrials.gov registry entry for NCT05941793 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oneness Biotech Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild to Moderate COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05941793 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Other, Utah.
Frequently Asked Questions
What is clinical trial NCT05941793 about?
NCT05941793 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients". A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants with Mild to Moderate COVID-19
What is the current status of trial NCT05941793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2023-09-11. Estimated completion is 2024-08-12.
What conditions does trial NCT05941793 study?
This clinical trial studies the following conditions: Mild to Moderate COVID-19.
What interventions are being tested in trial NCT05941793?
The interventions under investigation include: Placebo (DRUG), MBS-COV (DRUG).
Who is sponsoring clinical trial NCT05941793?
This trial is sponsored by Oneness Biotech Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05941793 being conducted?
This trial has 5 study locations across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.